EFFICACY &
SAFETY

Helps relieve multiple occasional stomach upsets†
and demonstrated to be safe and well tolerated 1,2,*

 

EFFICACY &
SAFETY

Helps relieve multiple occasional stomach upsets† and demonstrated to be safe and well tolerated 1,2,*

 

 

 

 

 

 

 

 

 

 

EFFECTIVE AT HELPING RELIEVE OCCASIONAL
STOMACH UPSETS:1,2,†, *

IB-Yellow-Check-Mark

 INDIGESTION

IB-Yellow-Check-Mark

 BLOATING

IB-Yellow-Check-Mark

 ABDOMINAL  DISCOMFORT +           
    CONSTIPATION/DIARRHEA

IB-Yellow-Check-Mark

 HEARTBURN

IB-Yellow-Check-Mark

 NAUSEA

IB-Yellow-Check-Mark

 GAS

 

 

EFFECTIVE AT HELPING RELIEVE OCCASIONAL STOMACH UPSETS:1,2,†,*

IB-Yellow-Check-Mark

INDIGESTION

IB-Yellow-Check-Mark

BLOATING

IB-Yellow-Check-Mark

ABDOMINAL
DISCOMFORT +
CONSTIPATION/
DIARRHEA

IB-Yellow-Check-Mark

HEARTBURN

IB-Yellow-Check-Mark

NAUSEA

IB-Yellow-Check-Mark

GAS

IBEROGAST™ IS SUPPORTED BY A GROWING BODY OF CLINICAL EVIDENCE SPANNING DECADES

The efficacy and safety of Iberogast™️ in helping relieve occasional stomach upsets† has been shown in multiple studies over 3 decades, as well as a meta-analysis1,*

Timeline-Desktop
Timeline-Mobile

IBEROGAST™ PROVIDES CLINICALLY PROVEN DIGESTIVE RELIEF1,*

HELPS RELIEVE OCCASIONAL STOMACH UPSETS1,†,*

Clinically proven to deliver a statistically significant improvement in overall symptoms after 28 and 56 days of use.*

Subject data-based meta-analysis applying the latest guidelines

28-day_Improvement_desktop
28-day_Improvement_Mobile
56-day_Improvement_desktop
56-day_Improvement_Mobile

Improvement in overall symptoms vs baseline

Overall-Improvement_desktop
Overall-Improvement_Mobile

Study design

Meta-analysis of randomized, controlled, clinical studies testing IberogastTM, including data from patients with at least 1 of the following key symptoms at baseline: fullness, early satiety, or epigastric discomfort. Four randomized, controlled trials (including 613 patients) were identified, with 2 eligible for efficacy analysis: Madisch 2004 and Vinson 2020.

IBEROGAST™ IS DEMONSTRATED TO BE SAFE AND WELL TOLERATED

tolerability-table_desktop
tolerability-table_mobile
icon-correct

The tolerability and safety of IberogastTM  have been shown in multiple randomized, placebo-controlled clinical studies1,3,4,7

icon-correct

The safety profile of IberogastTM  is comparable to placebo1

   READ THE 2024 META-ANALYSIS   

RECOMMEND IBEROGAST™

Free patient coupons
and samples

Free patient coupons and samples

ORDER NOW

QUESTIONS ABOUT IBEROGAST™?

We’ve got answers

We’ve got answers

 

VISIT OUR FAQ

AE, adverse event; CI, confidence interval; GI, gastrointestinal.

†Helps relieve occasional: Indigestion, Bloating, Heartburn, Nausea, Gas, Abdominal Discomfort + Constipation/Diarrhea.*

‡This trial was published as an abstract and is not available online.

*This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

Expand All Collapse All
    References

    References: 1. Andresen V, Shah A, Fink C, Rabini S, Wargenau M, Holtmann G. Digestion. 2024;105(3):166-174. doi:10.1159/000535672 2. Data on file, Bayer HealthCare. 3. Vinson B, Fink C, Wargenau M, Talley NJ, Holtmann G. JGH Open. 2024;8(5):e13054. doi:10.1002/jgh3.13054 4. Madisch A, Holtmann G, Mayr G, Vinson B, Hotz J. Digestion. 2004;69(1):45-52. doi:10.1159/000076546 5. Madisch A, Holtmann G, Plein K, Hotz J. Aliment Pharmacol Ther. 2004;19(3):271-279. doi:10.1111/j.1365-2036.2004.01859.x 6. Rösch W, Vinson B, Sassin I. Z Gastroenterol. 2002;40(6):401-408. doi:10.1055/s-2002-32130 7. Buchert D. Z Phytotherapie. 1994;15(1):45-46.

    Image